Cart
sales@molnova.com
β-Amyloid 15-21
CAS No. ——
β-Amyloid 15-21( Beta-Amyloid (15-21) )
Catalog No. M29913 CAS No. ——
β-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease. This fragment is involved in beta sheet formation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Nameβ-Amyloid 15-21
-
NoteResearch use only, not for human use.
-
Brief Descriptionβ-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease. This fragment is involved in beta sheet formation.
-
Descriptionβ-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease. This fragment is involved in beta sheet formation.
-
In Vitro——
-
In Vivo——
-
SynonymsBeta-Amyloid (15-21)
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight852.03
-
Molecular FormulaC43H65N9O9
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:Gln-Lys-Leu-Val-Phe-Phe-Ala
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Neuropeptide S (huma...
Neuropeptide S human (TFA) is a potent endogenous neuropeptide S receptor agonist (EC50=9.4 nM).
-
Glaucine
Glaucine has antitussive antioxidative potential and antiviral activities it may be an anti-arthritic agent it can enhance LPS and zymosan-induced IL-10 production. Glaucine can inhibit the migration and invasion of human breast cancer cells by MMP-9 inhibitory activity attenuating IκBα and NF-κB activities.
-
2-Tridecanone
2-Tridecanone is a nonalkaloid insecticide isolated from the wild tomato Lycopersicon hirsutum f. glabratum. 2-Tridecanone is a volatile organic compound.
